RxDoctor Payments Data

Ronald Rinker, MD

Gastroenterology · Pascagoula, MSNPI 1740226117

Payments from drug & device makers

$2,438in general payments, 2019–2025

Across 134 payments — averaging $18.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$667
  • Intercept Pharmaceuticals, Inc.$279
  • Johnson & Johnson$258
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$223
  • Takeda Pharmaceuticals U.S.A., Inc.$178
  • Gilead$168
  • plus $663 from 13 others

What the payments were for

  • Food & beverage$2,40699%
  • Education$321%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,438 in reported general payments places this provider in the 30th percentile of 127 gastroenterology providers in Mississippi.

See all gastroenterology providers in Mississippi

Medicare billing

Part B allowed, 2024
$165,404
Medicare patients
933
Services billed
1,631

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab14$363,921
Humira(Cf) PenAdalimumab13$177,104
XifaxanRifaximin31$93,871
LinzessLinaclotide78$77,092
CreonLipase/Protease/Amylase19$44,682
ZenpepLipase/Protease/Amylase11$29,840
Pantoprazole Sodium1,530$21,594
Mesalamine39$13,496
Mesalamine ErMesalamine46$9,509
Sucralfate252$8,918
MovantikNaloxegol Oxalate17$7,502
Omeprazole567$7,485
Balsalazide Disodium53$5,914
Colesevelam Hcl50$5,901
Esomeprazole Magnesium109$4,594

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$258$363,92114 claims
AbbVieLinzess, Creon$667$121,77597 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$223$93,87131 claims
Redhill Biopharma Inc.Movantik$40$7,50217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 127 gastroenterology providers in Mississippi.

Other gastroenterology in Pascagoula

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →